TY - JOUR
T1 - Maternal Views on RSV Vaccination During the First Season of Implementation in England and Scotland
AU - Williams, Thomas C
AU - Marlow, Robin
AU - Cunningham, Steve
AU - Drysdale, Simon B
AU - Groves, Helen
AU - Iskander, Dalia
AU - Liu, Xinxue
AU - Lyttle, Mark D
AU - Mpamhanga, Chengetai D.
AU - O'Hagan, Shaun
AU - Waterfield, Thomas
AU - Roland, Damian
PY - 2025/1/29
Y1 - 2025/1/29
N2 - Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTI) in infants less than 6 months old, resulting in an estimated 1.4 million hospital admissions each year worldwide1. A maternal bivalent RSV prefusion F protein–based (RSVpreF) vaccine was introduced to the United Kingdom routine immunization schedule in the summer of 2024; this was offered as part of antenatal care by midwife led maternity services (Scotland and England), and in some areas, in primary care also (England only). The impact of such a vaccine will depend not just on the effectiveness of the vaccine itself, but also on uptake of the vaccine by recipients. As part of the BronchStop vaccine effectiveness study2 we conducted a survey of mothers eligible for RSV vaccination whose infants had been admitted to hospital with bronchiolitis or a LRTI, designing a questionnaire around the 5Cs of vaccine hesitancy (for further details of study design see Supplementary File 2). Here we present initial results from this survey to facilitate counselling of pregnant women who are offered the RSVpreF vaccination and inform vaccine uptake strategies.
AB - Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTI) in infants less than 6 months old, resulting in an estimated 1.4 million hospital admissions each year worldwide1. A maternal bivalent RSV prefusion F protein–based (RSVpreF) vaccine was introduced to the United Kingdom routine immunization schedule in the summer of 2024; this was offered as part of antenatal care by midwife led maternity services (Scotland and England), and in some areas, in primary care also (England only). The impact of such a vaccine will depend not just on the effectiveness of the vaccine itself, but also on uptake of the vaccine by recipients. As part of the BronchStop vaccine effectiveness study2 we conducted a survey of mothers eligible for RSV vaccination whose infants had been admitted to hospital with bronchiolitis or a LRTI, designing a questionnaire around the 5Cs of vaccine hesitancy (for further details of study design see Supplementary File 2). Here we present initial results from this survey to facilitate counselling of pregnant women who are offered the RSVpreF vaccination and inform vaccine uptake strategies.
U2 - 10.1016/S1473-3099(25)00060-X
DO - 10.1016/S1473-3099(25)00060-X
M3 - Article
SN - 1473-3099
VL - 25
SP - e135-e136
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 3
ER -